glatiramer acetate

(redirected from Copolymer 1)

glatiramer acetate


Pharmacologic class: Immunomodulator

Therapeutic class: Multiple sclerosis agent

Pregnancy risk category B


Unknown. Thought to alter immune processes believed to be responsible for pathogenesis of multiple sclerosis.


Injection: 20 mg lyophilized glatiramer acetate and 40 mg mannitol in single-use 2-ml vial (1-ml vial of sterile water for injection included for reconstitution)

Indications and dosages

To reduce frequency of relapses in relapsing-remitting multiple sclerosis

Adults: 20 mg/day subcutaneously


• Hypersensitivity to drug


Use cautiously in:
• pregnant or breastfeeding patients
• children (safety and efficacy not established).


• Give only by subcutaneous injection into arms, abdomen, hips, or thighs.
• Administer immediately after preparing. Discard unused portion.

Adverse reactions

CNS: abnormal dreams, agitation, anxiety, confusion, emotional lability, migraine, nervousness, speech disorder, stupor, tremor, weakness, vertigo

CV: chest pain, hypertension, palpitations, tachycardia, peripheral edema

EENT: eye disorder, nystagmus, ear pain, rhinitis

GI: nausea, vomiting, diarrhea, anorexia, gastroenteritis, other GI disorder, oral candidiasis, salivary gland enlargement, ulcerative stomatitis

GU: urinary urgency, hematuria, erectile dysfunction, amenorrhea, dysmenorrhea, menorrhagia, abnormal Papanicolaou smear, vaginal candidiasis, vaginal hemorrhage

Hematologic: ecchymosis, lymphadenopathy

Musculoskeletal: joint, back, or neck pain; foot drop; hypertonia

Respiratory: bronchitis, dyspnea, hyperventilation

Skin: eczema, erythema, diaphoresis, pruritus, rash, skin atrophy, skin nodules, urticaria, warts

Other: dental caries, facial edema, weight gain, herpes simplex, herpes zoster, cysts, chills, flulike symptoms, pain at injection site


None reported

Patient monitoring

Assess for immediate postinjection reaction, including flushing, chest pain, anxiety, breathing problems, and hives.
• Watch for transient chest pain, but be aware that this problem doesn't seem to be clinically significant.
• Check for vaginal bleeding.
• Watch for signs and symptoms of infection.

Patient teaching

• Teach patient how to prepare and self-administer drug. Supervise him the first time he does so.

Teach patient to recognize and immediately report signs and symptoms of postinjection reaction. Tell him this reaction may occur right away or up to several months after first dose.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Instruct patient to report signs or symptoms of infection or vaginal hemorrhage.
• Provide dietary counseling. Refer patient to dietitian if adverse GI effects significantly affect food intake.
• As appropriate, review all other significant and life-threatening adverse reactions.

glatiramer acetate (glahtear´a-meer as´ətāt),

n a medication used to decrease or stop a relapse of multiple sclerosis. It is typically used to treat individuals resistant to the effects of interferon-β.
References in periodicals archive ?
A Food and Drug Administration advisory committee recommended that the agency approve one of the group's decoys, copolymer 1, as a treatment for MS.
If approved, copolymer 1 would be the third drug in 3 years okayed for the treatment of MS, an incurable disease known for intermittent and progressively more severe episodes of pain and paralysis.
Like the interferons, copolymer 1 cuts the number of MS episodes by about one-third.
Made of a combination of four amino acids, copolymer 1 was developed for clinical use by Israeli chemical giant Teva Pharmaceutical Industries.
In measuring the effect on disability (as measured by one unit on the Expanded Disability Status Scale), significantly more patients taking Copolymer 1 improved (27.
of Ronkonkoma, New York (NASDAQ/NNM:HMIS) TEVA will offer insurance guidance and information to patients enrolled in a Treatment Investigational New Drug Program (T-IND) now under way to evaluate its investigational drug copolymer 1 in relapsing remitting (RR) multiple sclerosis.
We're pleased to be able to offer our T-IND patients this valuable service, especially our assistance in exploring insurance reimbursement for copolymer 1," said Richard J.
On clearance from the FDA, TEVA plans to market copolymer 1 under the brand name COPAXONE\.
Bromine contents (comonomer contents) of the copolymer 1 and copolymer 2 are 6 w% (4.
Tm of specimens of homopolymer and copolymer 1 are 224 and 216 [degrees] C respectively.
Typical stress-strain curves of annealed PTMT homopolymer, copolymer 1 and copolymer 2 are shown in Figs.
The low annealing temperature of 150 [degrees] C of copolymer 2 which was 30 [degrees] C lower than copolymer 1 and PTMT homopolymer resulted in a slower increase of intrinsic viscosity of copolymer 2 as a result of annealing.